Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2022 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas

VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
April 27, 2022 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, April 27, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based...
April 12, 2022 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR) Annual General Meeting

VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
March 30, 2022 09:16 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas

VANCOUVER, British Columbia, March 30, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
March 09, 2022 10:56 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)

VANCOUVER, British Columbia, March 09, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
January 25, 2022 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics President to Join Expert Panel at the Fifth Annual DDR, ATR & PARP Inhibitors Summit

VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
January 06, 2022 17:01 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022

VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
December 21, 2021 09:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents

VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
November 23, 2021 17:25 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
November 16, 2021 08:30 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Partners with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer

VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right